EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Resonance Health Ltd (RHT) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Resonance Health Ltd A$0.06, price A$0.07, upside -16.2%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · AU · ISIN AU000000RHT2

RH Thin data Sep 23, 2026

Resonance Health Ltd

RHT · AU

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value A$0.0553 · Overvalued (−16%)
!Quality 55/100
!Mixed Growth (revenue 5y +24.7 %/yr)
!Thin margins · 5.6% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers (8/13)
!Narrow moat 42/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 12 out of 100
!Weak on past: 29 out of 100
Watch Resonance Health Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.2000 A$0.0330 Fair Value A$0.0553 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range A$0.0330 – A$0.2000 · fair‑value band A$0.0423 – A$0.0683 · the A$0.0660 price screens above the A$0.0553 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Resonance Health in your weekly email

Every Wednesday you see whether Resonance Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments.

Show more

Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC; HepaFatScan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; HepaFatSmart, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFatSmart into a consolidated report; and CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading. It also provides phantoms comprising FerriScan, R2*/T2*, T1CMR, and T2CMR phantoms for the calibration of MRI machines. In addition, the company operates as an imaging contract research organization that provides comprehensive proposal and project management support, site set-up, imaging charter development, clinical reports, data transfer agreements, and compliance services for clinical trial sponsors. It serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.

Stock analysis

Resonance Health Ltd (RHT) currently trades at A$0.0660, while our model-based Fair Value estimate is A$0.0553, implying the stock looks roughly 19.3% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of A$0.0500 per share, and 0 of the 7 models we run sit above the A$0.0660 price.

Bear case: the Asset-Based group reads lowest at A$0.0100, and 7 of the 7 models stay below the price. Evidence for this calculation is low.

Scenario range: A$0.0423 (bear) to A$0.0683 (bull), the price of A$0.0660 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Resonance Health Ltd reported revenue of A$11.1M in FY2025 versus A$3.8M in FY2021, a compound +30.8%/yr. Reported net income was −A$1.7M in FY2025.

Key figures

Market cap A$30.1M (≈ $21.2M) · P/S ratio 1.55 · Net margin −15.7% · Return on equity 7.3% · Return on assets (EBIT) −8.7% · Operating margin 15.6% · Revenue (TTM) A$13.8M · Revenue growth (YoY) +53.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 1% below its 52-week high and 83% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −16%, RHT screens cheaper than that median.

Fair Value models

Bear A$0.0423 Fair Value A$0.0553 Bull A$0.0683
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF A$0.0400 A$0.0600 A$0.1100 78
Growth DCF A$0.0300 A$0.0600 A$0.1100 75
5Y Revenue Exit A$0.0200 A$0.0400 A$0.0700 69
All 7 models by family
DCF Models
FCF DCF A$0.0400 A$0.0600 A$0.1100 78
5Y Revenue Exit A$0.0200 A$0.0400 A$0.0700 69
10Y Revenue Exit A$0.0300 A$0.0500 A$0.0700 66
Multiples
EV/Revenue A$0.0200 A$0.0200 A$0.0300 54
Asset-Based
NCAV (Graham) A$0.0100 A$0.0100 A$0.0200 52
Growth DCF
Growth DCF A$0.0300 A$0.0600 A$0.1100 75
Rev-Margin DCF A$0.0300 A$0.0400 A$0.0800 69

Open the full fair value analysis →

Notify me when RHT reaches fair value

Put RHT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 55/100

Of which business quality 53 · Market factors (momentum, volatility) 78

Profitability 28
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 46
Earnings quality: real cash, not paper profit
Fin. Strength 55
Balance sheet, leverage, solvency risk
Investment 71
Disciplined investing over empire-building
Low Volatility 28
Calm price path (market factor)
Momentum 99
Price trend over the last 3–12 months (market factor)
52W Momentum 99
Distance to the 52-week high (market factor)
Net Issuance 85
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+28.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.7%
Start year 2020 (pandemic). Over 10 years: +16.3% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−32.2% (2020) → −17.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about +17.5% a year for the price.

RHT screens 19% overvalued. Compare with Veeva Systems Inc →

Compare Resonance Health Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 134 stocks

Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside −15% · Above median
Profitability
Return on equity (TTM) 7% · Above median
Return on assets 3% · Above median
Net margin (TTM) 6% · Above median
Operating margin (TTM) 16% · Top 25%
Growth and dividend
Revenue growth 53% · Top 25%
Balance sheet
Debt / equity 0.27× · Highest 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 2.22× · Pricier than median
P/S (TTM) 1.51× · Cheaper than median
P/FCF 25.9× · Pricier than median
EV/EBITDA 18.2× · Pricier than median
PEG 2.55× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 3
FUTURE (revenue growth)100 · sector 34
PAST (return on equity)29 · sector 5
HEALTH (low debt)87 · sector 98
DIVIDEND (yield)0 · sector 48

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $270.75 $297.83 +10%
Pro Medicus Limited PME A$161.31 A$64.50 −60%
BrightSpring Health Services, Inc BTSG $56.55 $26.07 −54%
HealthEquity, Inc HQY $91.75 $100.93 +10%
Hinge Health, Inc HNGE $94.15 $51.66 −45%
10x Genomics, Inc TXG $80.70 $21.71 −73%
Waystar Holding WAY $25.63 $28.19 +10%
XtalPi Holdings 2228 HK$8.39 HK$1.50 −82%
Doximity, Inc DOCS $26.51 $31.41 +18%
Privia Health Group PRVA $19.46 $5.26 −73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Resonance Health Ltd · Fair Value
A$0.0553 −19%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Resonance Health Ltd Fair Value". https://www.fairvalue-calculator.com/stock/RHT

Frequently asked questions

Is Resonance Health Ltd (RHT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of A$0.0553 versus a price of A$0.0660, about −16% upside (overvalued).
What is the fair value of RHT?
Our model-based fair value for Resonance Health Ltd is A$0.0553 (as of Sep 23, 2026), built from audited fundamentals. The current price: A$0.0660.
What is the quality score of RHT?
Resonance Health Ltd has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Resonance Health Ltd (RHT)?
Our model-based price target is the fair value of A$0.0553 (as of Sep 23, 2026) from 7 valuation models. Cautious scenario A$0.0423, optimistic scenario A$0.0683. It is a calculation from audited fundamentals, not an analyst target.
What is the Resonance Health Ltd stock forecast for 2026?
Our models put fair value at A$0.0553, about −16% upside versus a price of A$0.0660 (overvalued). Cautious scenario A$0.0423, optimistic scenario A$0.0683. The calculation is refreshed regularly with new filings.
What is the revenue of Resonance Health Ltd (RHT)?
Resonance Health Ltd reported trailing-twelve-month revenue of about A$13.8M (latest available figure, as of Sep 23, 2026).
What growth is priced into Resonance Health Ltd (RHT)?
For today's price to be fair in a discounted-cash-flow model, Resonance Health Ltd would have to grow free cash flow by +20.9 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +24.7 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of RHT use?
Our models discount Resonance Health Ltd at 9.7 %: a base by market capitalisation (nano), damped by beta 1.08, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Resonance Health Ltd that is +20.9 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Resonance Health Ltd (RHT) delivered so far?
Over the past 5 years revenue at Resonance Health Ltd grew +24.7 % a year. The price currently implies +20.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Resonance Health Ltd (RHT) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Resonance Health Ltd (+20.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Resonance Health Ltd (RHT)?
The free-cash-flow yield on the price is 2.68 %: that much free cash flow Resonance Health Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Resonance Health Ltd (RHT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Resonance Health Ltd it is A$0.0553 per share (as of Sep 23, 2026), against a price of A$0.0660. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Resonance Health Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, RHT trades above its calculated fair value: price A$0.0660, fair value A$0.0553, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RHT?
No. The price is what the market pays today (A$0.0660); the fair value is what the company's own numbers justify (A$0.0553). For Resonance Health Ltd the two are A$0.0107 per share apart. That gap is exactly why we show both numbers side by side.
How much is Resonance Health Ltd worth?
The market values Resonance Health Ltd at about A$30.1M (market capitalisation, as of Sep 23, 2026). Per share that is A$0.0660; our models calculate a fair value of A$0.0553 per share.
What do the bullish and bearish scenarios say about RHT?
Our models span a range for Resonance Health Ltd: cautious scenario A$0.0423, base A$0.0553, optimistic A$0.0683 per share (as of Sep 23, 2026, price A$0.0660). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of RHT?
The PEG ratio of Resonance Health Ltd is 2.55 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Resonance Health Ltd (RHT)?
Balance-sheet figures for Resonance Health Ltd (as of Sep 23, 2026): return on equity 7.3%, debt of 0.27 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is RHT from its 52-week high?
Resonance Health Ltd trades at A$0.0660, about 1% below its 52-week high of A$0.0670 and 83% above the low of A$0.0360 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0553 is for.
Which stocks are comparable to Resonance Health Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Resonance Health Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price A$0.0660, calculated fair value A$0.0553 (−16%), Quality Score 55/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RHT calculated?
We run Resonance Health Ltd through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0553, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Resonance Health Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Resonance Health Ltd (RHT)?
The closing price on Sep 24, 2026 was A$0.0660. Our model-based fair value is A$0.0553, about −16% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Resonance Health Ltd right now?
Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Resonance Health Ltd

How large is the market capitalisation of Resonance Health Ltd (RHT)?
The market capitalisation of Resonance Health Ltd is A$30.1M (≈ $21.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Resonance Health Ltd (RHT)?
The price-to-sales ratio of Resonance Health Ltd is 1.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Resonance Health Ltd (RHT)?
The net margin of Resonance Health Ltd is −15.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Resonance Health Ltd (RHT)?
The return on equity (ROE) of Resonance Health Ltd is 7.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Resonance Health Ltd (RHT)?
On an EBIT basis the return on assets of Resonance Health Ltd is −8.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Resonance Health Ltd (RHT)?
The operating margin of Resonance Health Ltd is 15.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Resonance Health Ltd (RHT)?
Revenue at Resonance Health Ltd is growing +53.1% versus a year earlier (3y avg +42.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Resonance Health Ltd (RHT)?
Earnings per share at Resonance Health Ltd are growing +5.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Resonance Health Ltd (RHT) carry?
The net debt of Resonance Health Ltd is A$826K (fiscal year 2025, ≈ 1.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Resonance Health Ltd in the live analysis

One click puts Resonance Health Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.